Submission guidelines
Instructions for Authors
Types of papers
It is the policy of Acta Diabetologica to ensure balance, independence, objectivity and scientific rigor in the journal. All authors are expected to disclose to the readers any real or apparent conflict of interest that may have a direct bearing on the subject matter of the article. It is mandatory for any type of paper to publish a conflict statement in the article itself, and to submit the conflict disclosure form in addition (you can find the form on the journal’s homepage on springer.com).
Editorials
are usually written by members of the Editorial and Advisory Board. They should not exceed 500 words, not include more than 1 illustration and references should be limited to 5.
Reviews
Reviews are usually invited, although unsolicited reviews may be considered for publication. Authors hoping to submit an unsolicited review should first consult the Editors-in-Chief at bex.chang@biomedcentral.com .
Proposals should include an abstract or detailed summary and a full outline of the review, along with a full author list with titles, affiliations and areas of expertise.
Review Articles are subject to the peer review process. Text length must not exceed 4,000 words. The number of references should not exceed 70 . Up to 15 figures are allowed. The abstract does not need to be structured.
Clinical Trials, Systematic Reviews and Meta-Analyses
Acta Diabetologica supports initiatives to improve the performance and reporting of trials, part of which includes prospective registering and numbering of clinical trials. The International Committee of Medical Journal Editors (ICMJE) has implemented the World Health Organisation (WHO) definition of clinical trials which states that a clinical trial is any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes. This definition includes phase I to Phase IV trials.
All clinical trials submitted to Acta Diabetologica must be registered with an approved ICMJE clinical trial registry (such as clinicaltrials.gov); Acta Diabetologica accepts registration of clinical trials in any of the primary registries that participate in the World Health Organization International Clinical Trial Registry Platform. Authors must include the unique clinical trial number and the name of the registry on the manuscript’s title page.
Authors of reports on randomized controlled trials (RCTs) are required to complete the checklist outlined in the Consolidated Standards of Reporting Trials (CONSORT) Statement. The instructions and checklist are designed to ensure that information pertinent to the trial is included in the study report. Acta Diabetologica requires that the CONSORT checklist is submitted with RCT manuscripts; CONSORT information may be posted with accepted manuscripts as online-only supplementary materials at the request of the editors or the authors.
Authors of reports on systematic reviews and meta-analyses are required to complete the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). The PRISMA Statement consists of a 27-item checklist and a four-phase flow diagram that have been developed to help authors improve the reporting of systematic reviews and meta-analyses. Acta Diabetologica requires that the completed checklist and diagram are submitted with systematic reviews and meta-analyses; PRISMA information may be posted with accepted manuscripts as online-only supplementary materials at the request of the editors or the authors.
Perspectives
Perspectives discuss models and ideas from a personal but balanced viewpoint. They are intended to stimulate discussion and new experimental approaches. As these are meant to express a personal viewpoint, with rare exceptions, Perspectives should have no more than two authors. Text length must not exceed 4,000 words. The number of references should not exceed 70 . Up to 5 figures are allowed. The abstract does not need to be structured.
Position statement
A position statement is written by experts on a specific topic of interest in the clinical practice of diabetes and associated disorders.
Original papers
should have a structured abstract (Aims, Methods, Results and Conclusions), must not exceed 3,000 words and should not include more than 6 illustrations and tables. Each separate part of a figure (a, b, etc.) counts as an illustration. Up to 45 references are permitted..
Case reports
They must not exceed 2,000 words, 5 references and 5 authors. They should not have an abstract, not include more than 2 illustrations.
Short communications
They must not exceed 1,000 words, should not have an abstract. They should not exceed 1,000 words; 2 illustrations and up to 5 references are permitted.
Letters to the editors
must not exceed 600 words (and 5 references) with one table or figure and without abstracts. They should be addressed to the Editors-in-Chief. Submitted letters will be subject to shortening and editorial revision.
The submission of manuscripts is via Editorial Manager. Please use the following
Link
Manuscript Submission
Submission of a manuscript implies: that the work described has not been published before; that it is not under consideration for publication anywhere else; that its publication has been approved by all co-authors, if any, as well as by the responsible authorities – tacitly or explicitly – at the institute where the work has been carried out. The publisher will not be held legally responsible should there be any claims for compensation.
Permissions
Authors wishing to include figures, tables, or text passages that have already been published elsewhere are required to obtain permission from the copyright owner(s) for both the print and online format and to include evidence that such permission has been granted when submitting their papers. Any material received without such evidence will be assumed to originate from the authors.
Online Submission
Please follow the hyperlink “Submit manuscript” on the right and upload all of your manuscript files following the instructions given on the screen.
Please ensure you provide all relevant editable source files. Failing to submit these source files might cause unnecessary delays in the review and production process.
Title Page
Please make sure your title page contains the following information.
Title
The title should be concise and informative.
Author information
The name(s) of the author(s)
The affiliation(s) of the author(s), i.e. institution, (department), city, (state), country
A clear indication and an active e-mail address of the corresponding author
If available, the 16-digit ORCID of the author(s)
If address information is provided with the affiliation(s) it will also be published.
For authors that are (temporarily) unaffiliated we will only capture their city and country of residence, not their e-mail address unless specifically requested.
Abstract
Please provide an abstract of 150 to 250 words. The abstract should not contain any undefined abbreviations or unspecified references.
For life science journals only (when applicable)
Trial registration number and date of registration
Trial registration number, date of registration followed by “retrospectively registered”
Keywords
Please provide 4 to 6 keywords which can be used for indexing purposes.
Declarations
All manuscripts must contain the following sections under the heading 'Declarations'.
If any of the sections are not relevant to your manuscript, please include the heading and write 'Not applicable' for that section.
To be used for all articles, including articles with biological applications
Funding (information that explains whether and by whom the research was supported)
Conflicts of interest/Competing interests (include appropriate disclosures)
Availability of data and material (data transparency)
Code availability (software application or custom code)
Authors' contributions (optional: please review the submission guidelines from the journal whether statements are mandatory)
Additional declarations for articles in life science journals that report the results of studies involving humans and/or animals
Ethics approval (include appropriate approvals or waivers)
Consent to participate (include appropriate statements)
Consent for publication (include appropriate statements)
Please see the relevant sections in the submission guidelines for further information as well as various examples of wording. Please revise/customize the sample statements according to your own needs.
Text
Text Formatting
Manuscripts should be submitted in Word.
Use a normal, plain font (e.g., 10-point Times Roman) for text.
Use italics for emphasis.
Use the automatic page numbering function to number the pages.
Do not use field functions.
Use tab stops or other commands for indents, not the space bar.
Use the table function, not spreadsheets, to make tables.
Use the equation editor or MathType for equations.
Save your file in docx format (Word 2007 or higher) or doc format (older Word versions).
Manuscripts with mathematical content can also be submitted in LaTeX.
LaTeX macro package (Download zip, 190 kB)
Headings
Please use no more than three levels of displayed headings.
Abbreviations
Abbreviations should be defined at first mention and used consistently thereafter.
Footnotes
Footnotes can be used to give additional information, which may include the citation of a reference included in the reference list. They should not consist solely of a reference citation, and they should never include the bibliographic details of a reference. They should also not contain any figures or tables.
Footnotes to the text are numbered consecutively; those to tables should be indicated by superscript lower-case letters (or asterisks for significance values and other statistical data). Footnotes to the title or the authors of the article are not given reference symbols.
Always use footnotes instead of endnotes.
Acknowledgments
Acknowledgments of people, grants, funds, etc. should be placed in a separate section on the title page. The names of funding organizations should be written in full.
Important note:
HbA1c values should be dually reported as “% (mmol/mol).” Please use the NGSP’s HbA1c converter (via the Link below) to calculate HbA1c values as both % and mmol/mol.
NGSP’s HbA1c converter
……
更多详情：
https://www.springer.com/journal/592/submission-guidelines
